CN106860907A - A kind of hemostatic gauze - Google Patents
A kind of hemostatic gauze Download PDFInfo
- Publication number
- CN106860907A CN106860907A CN201611264061.4A CN201611264061A CN106860907A CN 106860907 A CN106860907 A CN 106860907A CN 201611264061 A CN201611264061 A CN 201611264061A CN 106860907 A CN106860907 A CN 106860907A
- Authority
- CN
- China
- Prior art keywords
- hemostatic gauze
- hemostasis
- wound
- gauze
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to biomedicine field, more particularly to a kind of hemostatic gauze；Including being covered on injury wound to avoid outer bound pair wound from forming pollution while making effective ingredient enter the bed material portion of wound；It is covered in the hemostasis portion stopped blooding to wound in the bed material portion；The hemostasis portion is the mixture of fibrinogen and marine alga Extraction of Eucheuma gelatinae；The hemostatic gauze that this programme is provided employs a kind of new hemostatic factor, the hemostatic factor has preferable solubization, and the hemostatic gauze that this programme is provided stops blooding on the basis of biochemistry hemostasis with reference to physics, while providing various anti-inflammation and sterilization factors, infection is prevented from, promotes healing.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of hemostatic gauze.
Background technology
Blood is the necessary material of people living, but runs into fortuitous event in daily life sometimes, for example, cut the dish not small
It is anxious in one's hands or by sharp weapon scratch etc., cause human body wound and massive blood loss occur, if stopping blooding meeting not in time in this case
So that the condition of the injury of the wounded further deteriorates, or even death can be caused.Therefore first aid hemostasis and prevention infection one are to all by the world
The attention of various countries' medical field.
The main carriers form of existing hemostatic material is hemostatic gauze, stanch fibre band and tourniquet bandage.It is typical special
Sharp product has following several.
WO 01/28603 discloses a kind of injectable dosage formulations being related to for delivering composition, and said composition includes skeletonization
Albumen and hemostasis gelatin foam paste, the method for further relating to prepare the hemostasis gelatin foam paste for being adapted to injection BMP, the side
Method includes being hydrated Gelfoam powder with glutamate buffers.
It is related to skin biopsy tissue plug in the patents of US 5,394,886, wherein, the plug is be made of gelatin materials many
Hole sponge, wound is implanted into by it, its expansion, absorbs blood, and can be completely absorbed in patient's body.It is related to perforator
The combination of (blade for cutting skin) and plunger.The plunger for being used can be by commercial channel acquisition
Gelfoam .Gelfoam is the product obtained by commercial channel, and it can provide powdered gelatin, to be answered as styptic
Used in bleeding surface.The powdered gelatin is provided with the full glass jar with crown cap or pouch, respectively by it
Open, and its receiving material, i.e. gelatin are poured into sterile beaker or bowl.
US 5,645,849 discloses hemostatic plaster, and it includes biodegradable gelatin substrate, hemostasis promoting amount it is solidifying
Hemase and EACA.
JP 62221357 discloses the skin ointments for promoting anastalsis, and it includes dissolving thermoplastic in a solvent
Property resin or rubber, and including scattered jelly powder.The product is to include thermoplastic resin or rubber, and collagen, gelatin or
The ointment of shitosan fine powder.
FR 2679772 is related to for forming the granular materials of embolism, including scribbles hemostasis or coagulant
(thrombonicagent) polymer.The styptic can be jelly powder in small, broken bits.
US 6,096,309 is related to hemostatic composition, and it includes fibrin ferment and non-MC in aqueous medium
With the mixture of MC, wherein, the average fibril diameter of the MC is of about 3-30nm.
US 4,515,637 is related to the method for preparing collagen-fibrin ferment hemostatic composition, and is related to lyophilized collagen
Product, it includes collagen and fibrin ferment.
US 6,045,570 is related to be used as the jelly powder of styptic, and is related to biological sealer, and it includes gelatine size,
The gelatine size includes the gelatin powder for grinding.The slurry preferably includes Gelfoam powder, the powder be selected from salt solution
Diluent with water mixes.The slurry shows outstanding flow performance, i.e., it shows the dilatancy of minimum
(dilatency) can inject, and easily or import by catheter lumen, particularly small chamber.Therefore, the product has
Outstanding characteristic of fluid.
US 6,060,461 is related to particle, particularly glucan particles, and its granularity is 0.5-1000 μm, and averagely
Aperture is 0.5-1000 nm.This document disclose and used on wound in dry powder form by by the particle, can promote
Formation of the blood clotting on wound.
US 3,930,052 is related to varigrained cold water soluble gelatin composition.
US 5,225,536 is related to gelatin and amino acid granular.It has been said that such particle is adapted to and various mixed with resin.
The size distribution is such, and the granularity of most of particle is 1.5-9.0 μm.
US 2003/0012741 is related to the method for preparing micronizing collagen.It has been said that granularity should be no more than 20 μm, with
Just the adhesive force to wound surface is optimized.
As can be seen here, the Main Ingredients and Appearance of existing hemostatic material is gelatin and shitosan, and main carriers form is hemostatic yarn
Cloth, stanch fibre band, tourniquet bandage.But shitosan and gelatin are all water insoluble, and it is mainly reached only by calcium ion
The effect of blood, but calcium ion easy occluding vascular in blood, cause thrombus, and this can bring certain side effect.
So needing a kind of new hemostatic gauze, it mainly realizes hemostasis by water miscible hemostatic factor.
The content of the invention
It is an object of the invention to provide a kind of hemostatic gauze, it is intended to which the hemostasis composition for solving present hemostatic gauze is insoluble
In the problem of water.
What the present invention was realized in：A kind of hemostatic gauze, including be covered on injury wound to avoid outer bound pair from hindering
Mouth forms pollution makes effective ingredient enter the bed material portion of wound simultaneously；It is covered in being stopped blooding to wound in the bed material portion
Hemostasis portion；The hemostasis portion is the mixture of fibrinogen and marine alga Extraction of Eucheuma gelatinae.Carried by using marine alga Eucheuma
Thing is taken as new hemostasis composition, the marine alga Extraction of Eucheuma gelatinae is a kind of soluble hemostatic factor, existing stopping can be avoided
The water insoluble problem of blood factor.
Further technical scheme of the invention is：The hemostasis portion includes 1-5 parts of fibrinogen and 95-99 parts of sea
Algae Extraction of Eucheuma gelatinae.Increase the fibrinogen of fraction to play a part of auxiliary hemostasis.
Further technical scheme of the invention is：The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 1-54 parts；Marine alga
Protein 1-20 parts of complex salt of acid；1-10 parts of algin colloid；1-15 parts of alginic acid fat；1-96 parts of glue protein.
Further technical scheme of the invention is：Also include the gel section mixed with the hemostasis portion.The hemostasis portion
Itself it is a kind of liquid, in order to further improve the concentration in the hemostasis portion accommodated in bed material portion, can be by adding gel section
Mode causes the gelation of hemostasis portion.
Further technical scheme of the invention is：The gel section is calcium chloride.Caused by the calcium chloride of excessive addition
Hemostasis portion gelation, while calcium chloride also has certain anastalsis in itself.
Further technical scheme of the invention is：Also include anti-inflammatory factors.By adding anti-inflammatory factors so that the hemostasis
Gauze further realizes the effect of anti-inflammatory on the basis for realizing haemostatic effect.
Further technical scheme of the invention is：The anti-inflammatory factors are selected from Nano Silver, aspirin, acetparaminosalol
One or more in sweet smell, Diclofenac, Indomethacin, brufen, fenbufen.
Further technical scheme of the invention is：The nanometer silver concentration is 5-500 ppm.When using Nano Silver conduct
Nanometer silver concentration is set to during anti-inflammatory factors can play preferable effect for 5-500 ppm.
Further technical scheme of the invention is：The bed material portion is nonwoven gauze.Hemostasis portion needs in default of intensity
Depend on certain bed material, nonwoven gauze is relatively suitable as bed material, it is used, and scope is wide, with low cost, production technology
Simply.
Further technical scheme of the invention is：The bed material portion is degradable biological bandage.Hemostasis portion is in default of strong
Degree needs to depend on certain bed material, and degradable biological bandage is relatively suitable as bed material, and it is used, and scope is wide, low cost
Honest and clean, simple production process.
The beneficial effects of the invention are as follows：The hemostatic gauze that this programme is provided employs a kind of new hemostatic factor, the hemostasis
The factor has preferable solubization, and the hemostatic gauze that this programme is provided stops blooding on the basis of biochemistry hemostasis with reference to physics,
Various anti-inflammation and sterilization factors are provided simultaneously, infection is prevented from, promotes healing.
Specific embodiment
Present solution provides a kind of hemostatic gauze, including it is covered on injury wound to avoid outer bound pair wound from forming dirt
Dye makes effective ingredient enter the bed material portion of wound simultaneously；It is covered in the hemostasis portion stopped blooding to wound in the bed material portion；
The hemostasis portion is the mixture of fibrinogen and marine alga Extraction of Eucheuma gelatinae.By using marine alga Extraction of Eucheuma gelatinae conduct
New hemostasis composition, the marine alga Extraction of Eucheuma gelatinae is a kind of soluble hemostatic factor, can avoid existing hemostatic factor not
It is dissolved in the problem of water.
The hemostasis portion includes 1-5 parts of fibrinogen and 95-99 parts of marine alga Extraction of Eucheuma gelatinae.Increase fraction
Fibrinogen with play a part of auxiliary hemostasis.
The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 1-54 parts；1-20 parts of extra large alginic acid complex salt；Algin colloid
1-10 parts；1-15 parts of alginic acid fat；1-96 parts of glue protein.
Preferably, the hemostatic gauze also includes the gel section mixed with the hemostasis portion.The hemostasis portion is in itself
A kind of liquid, in order to further improve the concentration in the hemostasis portion accommodated in bed material portion, can be made by way of adding gel section
Must be stopped blooding portion's gelation.
The gel section is calcium chloride.The gelation of hemostasis portion is caused by the calcium chloride of excessive addition, while calcium chloride sheet
Body also has certain anastalsis.
The hemostatic gauze also includes anti-inflammatory factors.By adding anti-inflammatory factors so that the hemostatic gauze is being realized stopping blooding
The effect of anti-inflammatory is further realized on the basis of effect.
The anti-inflammatory factors are selected from Nano Silver, aspirin, acetparaminosalol sweet smell, Diclofenac, Indomethacin, Bu Luo
One or more in fragrant, fenbufen.
The nanometer silver concentration is 5-500 ppm.Nanometer silver concentration is set when using Nano Silver as anti-inflammatory factors
For 5-500 ppm can play preferable effect.
The bed material portion is nonwoven gauze.Hemostasis portion needs to depend on certain bed material in default of intensity, nonwoven
Gauze is relatively suitable as bed material, and it is used, and scope is wide, with low cost, simple production process.
The bed material portion is degradable biological bandage.Hemostasis portion in default of intensity need to depend on certain bed material it
On, degradable biological bandage is relatively suitable as bed material, and it is used, and scope is wide, with low cost, simple production process.
The validity of the hemostatic gauze that this programme is provided is illustrated followed by experimental data.
Experiment one：Design two groups of samples of A, B, Sample A first piece be hemostatic gauze, below four be common gauze, sample
B first pieces be common gauze, below four be common gauze.Include hemostasis portion and gel wherein in A groups sample on hemostatic gauze
Portion, wherein hemostasis portion include 1%（Mass fraction, similarly hereinafter）Fibrinogen and 99% marine alga Extraction of Eucheuma gelatinae, marine alga Qi
Unicorn acid extract includes 54% algal polysaccharides, 20% extra large alginic acid complex salt, 10% marine alga protein colloid, 15% alginic acid
Fat, 1% glue protein.Gel section is calcium chloride.Also contain the Nano Silver of 500 ppm.
Experiment carries out following operation：Dripped off with buret in ten seconds with 0.5 milliliter of pig blood, yarn is opened after 50 seconds
Cloth is checked.
As a result, A groups have shallow bloodstain in second gauze, but stop being permeated to the 3rd, and B groups are all thoroughly to the 5th.It can be seen that A
Group haemostatic effect is compared with B groups well.
Control experiment：With experiment one identical A, B, two groups of samples, wherein A groups first piece be hemostatic gauze, below four
Be common gauze, B groups first piece is common gauze, below four be common gauze, check experiment adds colour developing to refer to 0.5 milliliter of water
Show that agent was dripped off in ten seconds with buret, gauze inspection is opened after 50 seconds, as a result, two groups of A, B is thoroughly to the 5th.
Experiment two：Zoopery.
Experimental technique：The black pig one of microspecies is chosen, 15 are pierced into experiment pig limb artery position with 5 millimeters of cone of diameter
Mm depth, checks whether there is blood ejection after extraction, check that bloodstain permeates feelings after pushing down wound 5 minutes with ten identical test pieces
Condition.
This experiment, according to above method, makes after wound with hemostatic gauze ten and pushes down wound, 5 minutes first in left hind
Inspection result afterwards.Result is found in the 3rd hemostatic gauze hemostasis.Include hemostasis portion and gel section wherein on hemostatic gauze, wherein
Hemostasis portion includes 5%（Mass fraction, similarly hereinafter）Fibrinogen and 95% marine alga Extraction of Eucheuma gelatinae, marine alga kylin acid extract
Thing includes 25% algal polysaccharides, 10% extra large alginic acid complex salt, 5% marine alga protein colloid, 10% alginic acid fat, 50%
Glue protein.Gel section is calcium chloride.Also contain the Nano Silver of 250 ppm.
Then do wound in right hind with same method, then with common gauze ten push down wound, after 5 minutes the tenth according to
Right oozing of blood, does not have haemostatic effect.Repeat experimental result identical.
Experiment three：Zoopery.
Experimental technique：The black pig one of microspecies is chosen, 15 are pierced into experiment pig limb artery position with 5 millimeters of cone of diameter
Mm depth, checks whether there is blood ejection after extraction, check that bloodstain permeates feelings after pushing down wound 5 minutes with ten identical test pieces
Condition.
This experiment, according to above method, makes after wound with hemostatic gauze ten and pushes down wound, 5 minutes first in left hind
Inspection result afterwards.Result is found in the 9th hemostatic gauze hemostasis.Include hemostasis portion and gel section wherein on hemostatic gauze, wherein
Hemostasis portion includes 3%（Mass fraction, similarly hereinafter）Fibrinogen and 97% marine alga Extraction of Eucheuma gelatinae, marine alga kylin acid extract
Thing includes 1% algal polysaccharides, 1% extra large alginic acid complex salt, 1% marine alga protein colloid, 1% alginic acid fat, 96% glue
Protein.Gel section is calcium chloride.Also contain the Nano Silver of 100 ppm.
Then do wound in right hind with same method, then with common gauze ten push down wound, after 5 minutes the tenth according to
Right oozing of blood, does not have haemostatic effect.Repeat experimental result identical.
The hemostatic gauze that this programme is provided employs a kind of new hemostatic factor, and the hemostatic factor has preferable molten water
Property, the hemostatic gauze that this programme is provided stops blooding on the basis of biochemistry hemostasis with reference to physics, while provide various anti-inflammatory killing
Bacteria factor, is prevented from infection, promotes healing.
Presently preferred embodiments of the present invention is the foregoing is only, is not intended to limit the invention, it is all in essence of the invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Claims (10)
1. a kind of hemostatic gauze, it is characterised in that：Including being covered on injury wound to avoid outer bound pair wound from forming pollution
Effective ingredient is set to enter the bed material portion of wound simultaneously；It is covered in the hemostasis portion stopped blooding to wound in the bed material portion；Institute
It is fibrinogen and the mixture of marine alga Extraction of Eucheuma gelatinae to state hemostasis portion.
2. hemostatic gauze according to claim 1, it is characterised in that：The hemostasis portion includes 1-5 parts of fibrinogen
Marine alga Extraction of Eucheuma gelatinae with 95-99 parts.
3. hemostatic gauze according to claim 2, it is characterised in that：The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides
1-54 parts；1-20 parts of extra large alginic acid complex salt；1-10 parts of marine alga protein colloid；1-15 parts of alginic acid fat；1-96 parts of glue protein.
4. according to any described hemostatic gauze in claim 1-3, it is characterised in that：Also include being mixed with the hemostasis portion
Gel section.
5. hemostatic gauze according to claim 4, it is characterised in that：The gel section is calcium chloride.
6. according to any described hemostatic gauze in claim 1-3, it is characterised in that：Also include anti-inflammatory factors.
7. according to claim 6, it is characterised in that：The anti-inflammatory factors are selected from Nano Silver, aspirin, to acetyl ammonia
One or more in Ji Fen, Diclofenac, Indomethacin, brufen, fenbufen.
8. hemostatic gauze according to claim 7, it is characterised in that：The nanometer silver concentration is 5-500 ppm.
9. according to any described hemostatic gauze in claim 1-3, it is characterised in that：The bed material portion is nonwoven gauze.
10. according to any described hemostatic gauze in claim 1-3, it is characterised in that：The bed material portion is degradable biological
Bandage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611264061.4A CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611264061.4A CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106860907A true CN106860907A (en) | 2017-06-20 |
| CN106860907B CN106860907B (en) | 2019-10-29 |
Family
ID=59164674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611264061.4A Active CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860907B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5492618A (en) * | 1977-12-30 | 1979-07-23 | Japan Synthetic Rubber Co Ltd | Poultice |
| TW455492B (en) * | 1996-12-20 | 2001-09-21 | Johnson & Amp Johnson Medical | Bioresorbable alginate derivatives |
| CN1387920A (en) * | 2001-05-17 | 2003-01-01 | 庄臣及庄臣工商有限公司 | Adhesive bandage |
| CN101516301A (en) * | 2006-08-04 | 2009-08-26 | Stb救生技术公司 | Solid dressing for treating wounded tissue |
| CN103394078A (en) * | 2013-07-31 | 2013-11-20 | 中国人民解放军第四军医大学 | Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid |
-
2016
- 2016-12-30 CN CN201611264061.4A patent/CN106860907B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5492618A (en) * | 1977-12-30 | 1979-07-23 | Japan Synthetic Rubber Co Ltd | Poultice |
| TW455492B (en) * | 1996-12-20 | 2001-09-21 | Johnson & Amp Johnson Medical | Bioresorbable alginate derivatives |
| CN1387920A (en) * | 2001-05-17 | 2003-01-01 | 庄臣及庄臣工商有限公司 | Adhesive bandage |
| CN101516301A (en) * | 2006-08-04 | 2009-08-26 | Stb救生技术公司 | Solid dressing for treating wounded tissue |
| CN103394078A (en) * | 2013-07-31 | 2013-11-20 | 中国人民解放军第四军医大学 | Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106860907B (en) | 2019-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lan et al. | Chitosan/gelatin composite sponge is an absorbable surgical hemostatic agent | |
| TWI237573B (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| DE69333286T2 (en) | A THROMBIN BLOOD FRACTION FOR USE IN A MEDICAL PROCEDURE | |
| CN102600013B (en) | Medical flocking hemostasis material, preparation thereof and application | |
| CN101121041A (en) | Denaturated starch absorbable hemostatic material and preparation method thereof | |
| AU2015364375A1 (en) | Flowable hemostatic composition | |
| CN103520764A (en) | Functional dressing, and preparation method and application thereof | |
| CN104906626A (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
| CN101497670A (en) | Biocompatibility pre-gelatinized modified starch and preparation thereof | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| EP1292339A2 (en) | Liquid collagen hemostat | |
| JP7378486B2 (en) | Medical adhesives, their preparation methods, and their uses | |
| CN105816905A (en) | Absorbable bone wax with heal-promoting function and preparation method of absorbable bone wax | |
| CN103977449B (en) | A kind of blended liquid hemostatic composite and preparation method thereof | |
| US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
| CN108498855A (en) | A kind of antibacterial anti hemorrhagic colloidal sol and preparation method thereof | |
| ES2741015T3 (en) | Dry pad comprising thrombin and pectin | |
| CN106860907B (en) | A kind of hemostatic gauze | |
| CN107029280B (en) | A kind of preparation method of chitin-alginic acid salt soft capsule grain hemostatic material | |
| CN113797384B (en) | Preparation method of injection type bone repair agent | |
| CN113827778A (en) | Injection type bone repair agent and application thereof | |
| WO2021176457A1 (en) | Anti-hemorrhaging compositions | |
| CN106620660A (en) | Bleeding-stopping spray | |
| CN102266581B (en) | Absorbable hemostatic sealing material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |